Guy's and St Thomas' NHS Foundation Trust / King's Health Partners Cancer Centre
South London's cancer centre with King's College London, strong in breast and prostate cancer, radiotherapy and large screening trials such as NHS-Galleri.
Guy's Cancer Centre, opened in 2016, brings together cancer care for Guy's and St Thomas' and forms, with King's College London and King's College Hospital, the King's Health Partners Comprehensive Cancer Centre. King's School of Cancer and Pharmaceutical Sciences hosts the Breast Cancer Now Research Unit, where Andrew Tutt led clinical development of PARP inhibitors in BRCA-mutated breast cancer including the OlympiA trial, and the Cancer Prevention Trials Unit under Peter Sasieni, which runs the NHS-Galleri multi-cancer early detection trial with Cancer Research UK. The trust has one of the largest radiotherapy services in the UK, a leading robotic urology and prostate programme, and is part of the CRUK City of London Centre.
- Breast cancer and PARP inhibitors
- Cancer Prevention Trials Unit (NHS-Galleri)
- Prostate and urology
- Radiotherapy
- Haemato-oncology
Pages like this
not linked directly; found by shared links- PairingGermline BRCA test → adjuvant PARP inhibitor
Shares OlympiA, PARP inhibitors, Olaparib, Triple-negative breast cancer (TNBC).
- IdeaMulti-cancer blood test as the first step for patients with non-specific symptoms
Shares GRAIL, Galleri, Multi-cancer early detection (MCED).
- IdeaPre-agreed update rules so an MCED test is not obsolete when its trial reads out
Shares GRAIL, NHS-Galleri, Multi-cancer early detection (MCED).
- TermGermline BRCA mutation (gBRCA)
Shares OlympiA, PARP inhibitors, Olaparib, Triple-negative breast cancer (TNBC).
- InstitutionBreast Cancer Trials
Shares OlympiA, PARP inhibitors, Olaparib, Triple-negative breast cancer (TNBC).
- Key paperOlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer
Shares Andrew Tutt, OlympiA, PARP inhibitors, Olaparib.
- IdeaLet MCED trials read out on late-stage incidence, with mortality follow-up mandated
Shares NHS-Galleri, Galleri, Multi-cancer early detection (MCED).
- PersonJohann de Bono
Shares The Institute of Cancer Research, PARP inhibitors, Olaparib, Prostate cancer.